BPMC - Blueprint Medicines Corporation
| Previous Close | 67.83 |
| Open | 67.17 |
| Bid | 67.79 x 800 |
| Ask | 67.88 x 800 |
| Day's Range | 65.91 - 68.80 |
| 52 Week Range | 44.58 - 109.00 |
| Volume | 134,246 |
| Avg. Volume | 397,588 |
| Market Cap | 2.973B |
| Beta (3Y Monthly) | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.79 |
| Earnings Date | Feb 19, 2019 - Feb 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 98.50 |
- Markit•2 days ago
See what the IHS Markit Score report has to say about Blueprint Medicines Corp.
# Blueprint Medicines Corp ### NASDAQ/NGS:BPMC View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.89 billion over the last one-month into ETFs that hold BPMC are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•10 days ago
Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today
Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
- MarketWatch•10 days ago
Cancer stocks heat up after third big merger in the past month
The third multibillion-dollar buyout of cancer-treatment developers in the past month was a charm for the shares of targeted oncology companies, as Leerink analyst Andrew Berens said Eli Lilly’s deal to buy Loxo Oncology validated the “significant value and interest” in the sector.
- PR Newswire•13 days ago
Blueprint Medicines Announces "2020 Blueprint" Global Business Strategy and Outlines Key Corporate Goals
-- Top-line avapritinib data support planned NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST in first half 2019 -- -- Registration-enabling trials for avapritinib in advanced and indolent systemic ...
- Markit•28 days ago
See what the IHS Markit Score report has to say about Blueprint Medicines Corp.
# Blueprint Medicines Corp ### NASDAQ/NGS:BPMC View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding BPMC are favorable, with net inflows of $2.11 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•last month
Analysis: Positioning to Benefit within Quidel, Granite Construction, FireEye, Consolidated Edison, EnPro Industries, and Blueprint Medicines — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Dec. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Insider Monkey•last month
Is Blueprint Medicines Corporation (BPMC) A Good Stock To Buy?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]
Markit•last monthSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- Simply Wall St.•last month
Is Blueprint Medicines Corporation’s (NASDAQ:BPMC) CEO Overpaid Relative To Its Peers?
In 2014 Jeff Albers was appointed CEO of Blueprint Medicines Corporation (NASDAQ:BPMC). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we’ll Read More...
- PR Newswire•2 months ago
Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
- 83% overall response rate, with evidence of deepening of response over time - - Median duration of response not reached; 12-month duration of response rate of 76% - - Statistically significant improvements ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- PR Newswire•2 months ago
Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy
- 84% ORR in PDGFRα D842V GIST and 20% ORR in fourth-line or later GIST support plans to submit New Drug Application to FDA in the first half of 2019 - - 26% ORR in regorafenib-naïve third- and fourth-line ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of BPMC earnings conference call or presentation 30-Oct-18 12:30pm GMT
Q3 2018 Blueprint Medicines Corp Earnings Call
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind SkyWest, Blueprint Medicines, HP, Hewlett Packard Enterprise, Cardinal Health, and The Medicines — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•3 months ago
Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue Estimates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.73% and -45.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Blueprint Medicines: 3Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of $1.66 per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- PR Newswire•3 months ago
Blueprint Medicines Reports Third Quarter 2018 Financial Results
- Avapritinib receives Breakthrough Therapy Designation for treatment of advanced SM - - First patient screened in registration-enabling PATHFINDER trial in advanced SM - - Received FDA feedback supporting ...
- PR Newswire•3 months ago
Blueprint Medicines Strengthens Leadership with the Appointments of Christina Rossi as Chief Commercial Officer and Paul Beresford as General Manager, International
CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the appointment of Christina Rossi as Chief Commercial Officer, effective October 29, 2018. Blueprint Medicines also announced the appointment of Paul Beresford as General Manager, International. In her new role, Ms. Rossi will join the executive management team and have overall responsibility for commercial strategy and operations, including sales and marketing, for a potential commercial launch of avapritinib in the United States in 2019 and pre-commercial planning across Blueprint Medicines' pipeline.
Markit•3 months agoSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- PR Newswire•3 months ago
Blueprint Medicines to Report Third Quarter 2018 Financial Results on Tuesday, October 30, 2018
CAMBRIDGE, Mass., Oct. 23, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, October 30, 2018 to report its third quarter 2018 financial results and provide a corporate update. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call. Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases.
- Zacks•3 months ago
Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Markit•3 months agoSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
Short interest is low for BPMC with fewer than 5% of shares on loan. The net inflows of $1.69 billion over the last one-month into ETFs that hold BPMC are not among the highest of the last year and have been slowing.
- PR Newswire•3 months ago
Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers
90 percent of evaluable MTC and PTC patients had tumor reductions 62 percent response rate in MTC patients treated with 300 to 400 mg once daily for at least 24 weeks Patients with longest treatment durations ...
- PR Newswire•4 months ago
Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva
-- Expect to File an IND Application by end of 2018 -- -- Plan to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2019 -- CAMBRIDGE, Mass. , Oct. 1, 2018 /PRNewswire/ -- Blueprint ...
